Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05526755 · ClinicalTrials.gov registry record · Phase 2
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
A Phase 2 study of Stage II-IIIB Non-small Cell Lung Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
- 20
- Study locations
NCT05526755 is a Phase 2 study of Stage II-IIIB Non-small Cell Lung Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 188 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT05526755, a Phase 2 study of Stage II-IIIB Non-small Cell Lung Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the efficacy and safety of osimertinib in participants with EGFRm positive stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy.
Conditions Studied
Interventions
- DRUG Osimertinib 80 mg/40 mg
Study Locations (20)
Other
- Research Site - Hong Kong
- Research Site - Hong Kong
- Research Site - Hong Kong
- Research Site - Avellino
- Research Site - Brescia
- Research Site - Lecce
- Research Site - Milan
- Research Site - Naples
- Research Site - Palermo
- Research Site - Peschiera del Garda
- Research Site - Reggio Emilia
- Research Site - Sondrio
- Research Site - Terni
- Research Site - Udine
- Research Site - Kuala Lumpur
- Research Site - Kuantan
- Research Site - Kuching
California
- Research Site - Santa Rosa
Nevada
- Research Site - Las Vegas
New York
- Research Site - White Plains
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2029-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05526755
The ClinicalTrials.gov registry entry for NCT05526755 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stage II-IIIB Non-small Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Osimertinib 80 mg/40 mg is the first listed.
NCT05526755 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Nevada.
Frequently Asked Questions
What is clinical trial NCT05526755 about?
NCT05526755 is a clinical study titled "A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)". To assess the efficacy and safety of osimertinib in participants with EGFRm positive stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy.
What is the current status of trial NCT05526755?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2023-03-06. Estimated completion is 2029-11-22.
What conditions does trial NCT05526755 study?
This clinical trial studies the following conditions: Stage II-IIIB Non-small Cell Lung Carcinoma.
What interventions are being tested in trial NCT05526755?
The interventions under investigation include: Osimertinib 80 mg/40 mg (DRUG).
Who is sponsoring clinical trial NCT05526755?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05526755 being conducted?
This trial has 20 study locations across California, Nevada, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.